Komori
Kidswell Bio (4584) · RiskRestated

Risk of disputes over compensation for employee inventions

First written in FY2017. 7 of 8 entries say "Restated". Latest entry: FY2023-Q3.

8entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2023-Q32017: 220172018: 320182019: 120192020: 120202021: 020212022: 020222023: 1
Same theme, other companies
Risk of costs associated with patent ownership and inventor compensationA theme 8 companies write about · 8 as a headwind · 0 as a tailwind

6 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2023-Q3RestatedAnnual report

    「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」

    Discloses that there have been no material changes regarding the risk of disputes over compensation for employee inventions.
  2. FY2020RestatedAnnual report

    「If a payment arises in the future, a dispute may arise over the adequacy of the benefit.」

    Continues to disclose the risk of future disputes over the adequacy of compensation for employee inventions.
  3. FY2019RestatedAnnual report

    「No case requiring payment of the benefit has arisen to date, but if a payment arises in the future, a dispute may arise over the adequacy of the benefit.」

    Continues to disclose the risk of future disputes over the adequacy of compensation for employee inventions.
  4. FY2019-Q1RestatedAnnual report

    「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」

    Discloses that there have been no material changes regarding the risk of disputes over compensation for employee inventions.
  5. FY2018RestatedAnnual report

    「If a payment arises in the future, a dispute may arise over the adequacy of the benefit.」

    Continues to disclose the risk of future disputes over the adequacy of compensation for employee inventions.
  6. FY2018-Q3RestatedAnnual report

    「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    Discloses that there have been no material changes regarding the risk of disputes over compensation for employee inventions.
  7. FY2018-Q2RestatedAnnual report

    「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」

    Discloses that there have been no material changes regarding the risk of disputes over compensation for employee inventions.
  8. FY2017First statedAnnual report

    「No issues have arisen with inventors regarding the payment of compensation to date, but the possibility of future disputes over the adequacy of compensation for rights cannot be ruled out.」

    The payment of reasonable benefits to inventors for employee inventions and the risk of future disputes over the adequacy of such benefits are explicitly disclosed for the first time.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of disputes over compensation for employee inventions | Kidswell Bio Corporation (4584) | Komori